Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2018’, provides in depth analysis on Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology and Metabolic Disorders under development targeting Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

– The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects

– The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Boston Pharmaceuticals Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Celgene Corp

Daiichi Sankyo Co Ltd

Escalier Biosciences BV

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Johnson & Johnson

Lead Pharma Holding BV

LEO Pharma A/S

Lycera Corp

Maruho Co Ltd

Novartis AG

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Visionary Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Overview

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Boston Pharmaceuticals Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Celgene Corp

Daiichi Sankyo Co Ltd

Escalier Biosciences BV

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Johnson & Johnson

Lead Pharma Holding BV

LEO Pharma A/S

Lycera Corp

Maruho Co Ltd

Novartis AG

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Visionary Pharmaceuticals Inc

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Drug Profiles

A-213 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABBV-157 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0284 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-6000 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-172767 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD-12681 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRC-39815 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2981278 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMU-366 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-17 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-71 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3534 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-451 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-0186 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-55716 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTA-1701 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Nuclear Receptor ROR Gamma for Autoimmune Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit RORC for Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target ROR Gamma for Autoimmune Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR gamma for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RORC for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ROR Gamma for Gastrointestinal and Immunology Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Autoimmune Disorders and Psoriasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Psoriasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-1001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-2211 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGFTX-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMP-778 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Dormant Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Discontinued Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Product Development Milestones

Featured News & Press Releases

Jun 20, 2018: Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of ROR gamma t

Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 1701 at the BIO International Convention

May 30, 2018: Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting

May 21, 2018: Karo Pharma Receives Milestone Payment for RORgamma Project From Pfizer

May 16, 2018: Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model

Apr 26, 2018: Nuevolution obtains new data in its internal RORt program supporting effect in human inflammatory bowel diseases

Apr 17, 2018: Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting

Apr 05, 2018: Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting

Apr 03, 2018: Reata to Present Preclinical Data on RTA 1701, a Novel RORt Inverse Agonist, at Upcoming Immunology Conference

Mar 16, 2018: Reata to Present on its Autoimmune and Inflammatory Disorders Drug Candidate at the BIO Asia International Conference

Jan 04, 2018: Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab

Nov 21, 2017: Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments

Nov 07, 2017: Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer’s (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716

Oct 19, 2017: Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a

Oct 04, 2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1)

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AbbVie Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018

Pipeline by Biogen Inc, H2 2018

Pipeline by Boston Pharmaceuticals Inc, H2 2018

Pipeline by Brickell Biotech Inc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pipeline by Escalier Biosciences BV, H2 2018

Pipeline by Genentech Inc, H2 2018

Pipeline by Genfit SA, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by Lead Pharma Holding BV, H2 2018

Pipeline by LEO Pharma A/S, H2 2018

Pipeline by Lycera Corp, H2 2018

Pipeline by Maruho Co Ltd, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Nuevolution AB, H2 2018

Pipeline by Orphagen Pharmaceuticals Inc, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Phenex Pharmaceuticals AG, H2 2018

Pipeline by Reata Pharmaceuticals Inc, H2 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Pipeline by Visionary Pharmaceuticals Inc, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports